ImmuCell Corporation
ICCC
$9.99
$0.222.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.63M | 5.51M | 6.44M | 8.07M | 7.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.63M | 5.51M | 6.44M | 8.07M | 7.75M |
| Cost of Revenue | 4.72M | 3.14M | 3.63M | 4.71M | 4.92M |
| Gross Profit | 2.91M | 2.36M | 2.82M | 3.35M | 2.83M |
| SG&A Expenses | 1.41M | 1.65M | 1.42M | 1.48M | 1.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.88M | 5.49M | 5.88M | 6.95M | 7.13M |
| Operating Income | 742.00K | 20.10K | 569.60K | 1.12M | 621.40K |
| Income Before Tax | -2.85M | -135.30K | 503.80K | 1.45M | 520.60K |
| Income Tax Expenses | 3.30K | 4.50K | 1.90K | 1.90K | 6.00K |
| Earnings from Continuing Operations | -2.85M | -139.70K | 501.90K | 1.45M | 514.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.85M | -139.70K | 501.90K | 1.45M | 514.60K |
| EBIT | 742.00K | 20.10K | 569.60K | 1.12M | 621.40K |
| EBITDA | 1.45M | 699.20K | 1.24M | 1.79M | 1.30M |
| EPS Basic | -0.32 | -0.02 | 0.06 | 0.16 | 0.06 |
| Normalized Basic EPS | 0.05 | -0.01 | 0.03 | 0.07 | 0.04 |
| EPS Diluted | -0.32 | -0.02 | 0.06 | 0.16 | 0.06 |
| Normalized Diluted EPS | 0.05 | -0.01 | 0.03 | 0.07 | 0.04 |
| Average Basic Shares Outstanding | 9.05M | 9.05M | 9.03M | 8.98M | 8.94M |
| Average Diluted Shares Outstanding | 9.19M | 9.05M | 9.03M | 8.98M | 8.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |